Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer. 30794721 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 Biomarker disease BEFREE RESULTS The most important biotargets for plumbagin in PC were identified as TP53, MAPK1, BCL2, and IL6. 31230062 2019
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 GeneticVariation disease BEFREE Through the biopsy histopathological examination, imaging examination, and genetic testing, the patient was diagnosed as metastatic PC with BRCA2 mutation. 31577767 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 Biomarker disease BEFREE The KPC mouse model, driven by the Kras and Trp53 transgenes, is well regarded for faithful recapitulation of human pancreatic cancer biology. 31780749 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 Biomarker disease BEFREE In this study, we investigated the relationship between SRPK2, Numb and p53 in the development of pancreatic cancer with or without chemical agent treatment in vitro. 30724469 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 Biomarker disease BEFREE Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. 31367258 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE We found that six novel tagging single-nucleotide polymorphisms (SNPs) (i.e, MAP2 rs35075084 T > deletion, PRKAG2 rs2727572 C > T and rs34852782 A > deletion, TP53 rs9895829 A > G, and RPTOR rs62068300 G > A and rs3751936 G > C) were significantly associated with an increased PanC risk. 30997723 2019
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 GeneticVariation disease BEFREE Olaparib is a PARP inhibitor (PARPi).For patients bearing BRCA1 or BRCA2 mutations, olaparib is approved to treat ovarian cancer and in clinical trials to treat breast and pancreatic cancers. 30660828 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 Biomarker disease BEFREE Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model. 30273070 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE In summary, our observations strongly indicated that, similarly to 2D monolayer culture, RUNX2 gene silencing increased GEM sensitivity of MiaPaCa‑2 spheres and highlighted the therapeutic potential of RUNX2 in pancreatic cancer with p53 mutation. 29620279 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 GeneticVariation disease BEFREE We confirmed variants in BRCA2 as the most common high-penetrant genetic factor associated with pancreatic cancer and we also identified candidate pancreatic cancer genes. 29074453 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE Detection of KRAS or p53 mutation in plasma is not an effective screening tool for pancreatic cancer because accumulation of multiple mutations is required for malignant transformation in the pancreas. 29303908 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 GeneticVariation disease BEFREE Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. 30407790 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05). 29922827 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 AlteredExpression disease BEFREE In this study, we demonstrate that inactivation of Cdkn2b (p15ink4b) is necessary for induction of pancreatic cancer by oncogenic KRAS<sup>G12D</sup> expression and inactivation of Tp53 and Cdkn2a in adult mouse pancreatic ductal cells (P60 or older). 28892048 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 GeneticVariation disease BEFREE Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. 29441441 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE K-ras<sup>LSL-G12D/+</sup>:: p53<sup>LSL-R172H/+</sup>:: Pdx-1-Cre (KPC) mice are an established model of pancreatic cancer that specifically express mutants of both K-ras and p53 in the pancreas by using Pdx-1-Cre. 28971839 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE Accumulating evidence strongly suggests that p53 mutations contribute to the acquisition and/or maintenance of drug-resistant property of pancreatic cancer. 29558908 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE Our work establishes a requirement for mutant p53 for the formation and maintenance of pancreatic cancer precursor lesions. 29367463 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE Together, this study highlights the therapeutic potential of NL in mutant p53 expressing pancreatic cancer. 29107110 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 GeneticVariation disease BEFREE Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05). 29922827 2018
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.800 AlteredExpression disease BEFREE In this study, we determined protein expression of BRCA1 and BRCA2 in 4 digestive system cancers (gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer) by immunohistochemistry on tissue microarrays. 29126833 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 GeneticVariation disease BEFREE We further show that class I HDACi induce senescence in pancreatic cancer cells with mutant p53. 27838375 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 Biomarker disease BEFREE In contrast, all animals with CI-lacking TP53 developed various subtypes of PC, including acinar cell carcinoma, ductal adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all died within 65 weeks. 27991926 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.800 Biomarker disease BEFREE Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy. 29211796 2017